Portage Biotech Inc. (PRTG)
NASDAQ: PRTG · Real-Time Price · USD
5.42
0.00 (0.00%)
Aug 4, 2025, 11:51 AM - Market open

Company Description

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.

Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor.

Portage Biotech Inc. is based in Tortola, British Virgin Islands.

Portage Biotech Inc.
Portage Biotech logo
CountryBritish Virgin Islands
Founded1973
IndustryBiotechnology
SectorHealthcare
Employees7
CEOAlexander Pickett

Contact Details

Address:
Clarence Thomas Building, P.O. Box 4649
Tortola, VG1110
British Virgin Islands
Phone302 219 5556
Websiteportagebiotech.com

Stock Details

Ticker SymbolPRTG
ExchangeNASDAQ
Fiscal YearApril - March
Reporting CurrencyUSD
CIK Code0001095435
CUSIP NumberG7185A128
ISIN NumberVGG7185A1286
SIC Code2834

Key Executives

NamePosition
Peter MolloyChief Executive Officer of Cyncado Therapeutics Inc.
Alexander PickettChief Executive Officer and Director
Dr. Robert A. Kramer Ph.D.Chief Scientific Officer
Adam MeleroController

Latest SEC Filings

DateTypeTitle
Aug 1, 2025S-8Securities to be offered to employees in employee benefit plans
Jul 28, 2025424B3Prospectus
Jul 25, 2025424B3Prospectus
Jul 25, 20256-KReport of foreign issuer
Jul 25, 202520-FAnnual and transition report of foreign private issuers
Jun 27, 2025424B3Prospectus
Jun 27, 20256-KReport of foreign issuer
Jun 27, 2025424B5Filing
Jun 25, 2025424B3Prospectus
Jun 25, 20256-KReport of foreign issuer